

#### **VETERANS ADMINISTRATION MARYLAND HEALTH CARE SYSTEM BALTIMORE DIVISION 10 NORTH GREENE STREET**

BALTIMORE, MD 21201

GEN000014.3

#### PATHOLOGY & LABORATORY MEDICINE SERVICE

#### **RETENTION OF RECORDS version 3** General Procedure # GEN00014

#### Principle:

This policy is to ensure that necessary records and documents of VAMHCS -P&LMS are adequately protected and maintained and to ensure that records that are no longer needed by VAMHCS-P&LMS or are of no value are discarded at the proper time.

#### Procedure:

- 1. Attached as Appendix A are The Record Retention Guidelines for Pathology & Laboratory Medicine- National Enforcement Program.
- 2. All records and materials must be maintained according to VA mandates unless otherwise required by accrediting agency (i.e. College of American Pathologists, CAP), Federal/State/Local regulations.
- 3. Should the laboratory cease testing, all records, slides, blocks, and tissues will be available at a local or remote storage site where that scope of service is offered.

#### Attachment(s):

Appendix A- Record Retention Guidelines for Pathology & Laboratory Medicine

#### References:

- 1. College of American Pathologists- General Checklist, August 17, 2016.
- 2. Pathology and Laboratory Medicine Service (P&LMS) Procedures-VHA HANDBOOK 1106.01, January 29, 2016.



#### VETERANS ADMINISTRATION MARYLAND HEALTH CARE SYSTEM BALTIMORE DIVISION 10 NORTH GREENE STREET BALTIMORE, MD 21201

GEN000014.3

DATE ADOPTED	Author of Procedure/Policy	Chief of Service
01/22/1996	Paul D. Gruver, MT	Signature: Dong H. Lee M.D.

Policy/Prod Retired:	edure(s)		Date retired:
Review Date	Version Number	Signature of reviewer	
11/8/11	3	godde.	
2			

**REVISION HISTORY** 

Date revised	Revision #	Changes made	Signature
09/30/15	2	Added New VA National Guidelines dated 08/12/15 version 2.2	LIF
10/31/17	3	Added item 3, reformatted	Mh



#### National Enforcement Office Operations Manual

Appendix A

# Record Retention Guidelines for Pathology & Laboratory Medicine

Warning! Uncontrolled on Paper

Version: 3.0

Page 1 of 15

**Document Status: Approved** 

Implementation Date: 2/14/2013	Supersedes: None
Author(s): Valerie McDowell	
Approval Date: 2/14/2013	Approved by: Michael Brophy
Signature: Original Signed	
Date Document Refired:	Superseded by:

Review Date: 10/18/2016
Review Date: 17/6/9
Review Date: 17/6/9

Reviewed by:

Reviewed by:

Review Date: 8/12/2015

Reviewed by: Valerie McDowell

Reviewed by: Valerie Mc Dowell

Reviewed by: Valerie McDowell

Review Date: 6/14/2014

**Document Review** 

Doc Type: GDL-520

Warning! Uncontrolled on Paper

Version: 3.0

Page 2 of 15

**Document Status: Approved** 

#### (Transfusion Medicine, Anatomic Pathology and Cytogenetic specific requirements listed separately) GENERAL/CLINICAL LABORATORY

ITEM	DISPOSITION	REFERENCE
Miscellany		
Test requisition/Test Orders/Accession log	2 years	RCS 10-1;7100.12, CAP GEN.20377, TJC DC.02.04.01 & AXA, 42CFR493.1105
Shipping manifests/packing lists (see Note 11)	3 months	GEN.40530
Test records (results, dates and names of testing personnel)	2 years	RCS 10-1;7100.13, CAP GEN.20377, TJC DC.02.04.01& WT.05.01.01 & AXA, 42CFR493.1105
Test report (Preliminary, Final and Corrected, including reference lab reports) (See Note 2)	2 years	RCS 10-1;7100-14, CAP GEN.20377, TJC DC.02.04.01 & AXA, 42CFR493.1105
Direct To Consumer test results and reference ranges	10 years	CAP GEN.41497, GEN.20377
Bone marrow reports	10 years	CAP HEM.36270 & TJC AXA
Quality control records  Reagents	2 years	RCS 10-1;7100.16, CAP GEN.20377, TJC DC.02.04.01 &EC.02.04.03 & WT.05.01.01 & AXA, 42CFR493.1105
<ul> <li>Instruments</li> </ul>		
Temperatures and other function checks		

Approved By: Kathy McLatchie

Doc Type: GDL-520

Authored By: Valerie McDowell 10/18/2016

Warning! Uncontrolled on Paper

Version: 3.0

Document Status: Approved

Page 3 of 15

Microbiology: If streamlined QC is used, documentation of test system verification and historical QC review	As long as streamlined QC is used but at least 2 years	CAP MIC.21626 (An individualized quality control plan (IQCP) including all required elements of IQCP, may be implemented by the laboratory to allow for the use of streamlined QC for commercial microbial identification systems (MIS))
Copies of the completed APHIS/CDC Forms, used to report identification of HHS select agents to CDC	3 years	42 CFR 73.6 (b) (3)
Flow Cytometry: Gated dot plots and histograms (See Note 10)	10 years	CAP FLO.23706 (Paper or electronic format is acceptable) &FLO.30605
Forensic records (see CAP checklist for listing of records)	At least 2 years or as	CAP CHM.38500
	long as legal action is pending	
Proficiency test records/applicable corrective action (See Note 6)	2 years	RCS 10-1;7100.16 & 7100.19, CAP GEN.20377 & COM.01700, TJC QSA.01.02.01 & AXA, 42CFR493.1105
Quality Management Records/Quality system assessments	2 years	RCS 10-1;7100.16, CAP GEN.20377, TJC DC.02.04.01, 42CRF493.1105
IQCP documents: risk assessment, validation data, and approved quality control plan.	2 years following discontinuation of	CAP Gen.20375
	the plan	
Discontinued test procedures (paper or electronic) with initial date of use and retirement dates	2 years (not blood bank or tissue)	RCS 10-1;7100.17, CAP COM.10500 & GEN.20375, TJC DC.02.01.01 & AXA, 42CFR493.1105
Instrument printouts and worksheets (See Note 1)	2 years	CAP GEN.20377, TJC DC 02.04.01 & AXA, 42CFR493.1105
Instrument preventative maintenance records: (daily/weekly/monthly/quarterly/semiannual)	2 years	RCS 10-1;7100.20, CAP GEN.20377, TJC EC.02.04.03, WT.05.01.01, AXA, 42CFR493.1105
Instrument/Method validation, records of method performance specifications (including validation of electronic/procedure/built-in QC)	2 years after discontinuation of the test	RCS 10-1; 7100.16 (2 years), CAP GEN.20377 (Life+2yrs), 42CFR493.1105 (life of instrument but no less than 2 years)
Instrument repair records (major repairs, parts and replacement) and annual preventive maintenance (PM's)	Life of instrument	RCS-10;7100.21 & TJC EC.02.04.03 & AXA
MSDS Sheets or a record identifying the chemical/substance and where & when it was used (see Note 7)	30 years	29 CFR 1910.1020

Approved By: Kathy McLatchie

Authored By: Valerie McDowell 10/18/2016

Doc Type: GDL-520

Warning! Uncontrolled on Paper

Version: 3.0

Page 4 of 15

**Document Status: Approved** 

Specimens		
Serum, heparinized and EDTA plasma, cerebrospinal fluid, body fluids	48 hours after results reported	RCS 10-1; 7100.23, TJC AXA, CAP GEN.20377 (does not include whole blood specimens such as blood gases)
Urine	24 hours	CAP GEN 20377, TJC AXA
Peripheral blood smears & body fluid smears	7 days	RCS 10-1; 7100.24, CAP GEN.20377, TJC AXA
Bone marrow smears	20 years	RCS-10; 7100.25 (20 years), CAP HEM.36270 (10 years)
Permanently stained slides for microbiology (e.g. Gram, Trichrome, etc	7 days	RCS 10-1; 7100.26, CAP GEN.20377, TJC AXA
Personnel		
Personnel records: qualifications, formal education, training, and competence, etc (As part of OPF)	30 years	RCS 10-1;7100.22
Initial training on an instrument/method	5 years	CAP GEN.20377 & GEN.55450 (2 years general lab 5 years blood bank), POC.06850 (2 years) RCS-10; 7100.22 (5 years)
Annual competency assessments	5 years	RCS 10-1;7100.22 (5 years), CAP GEN.20377 (2 years for clinical lab, 5 years for Blood Bank CAP considers these quality records)
Training records for Blood borne pathogens	3 years	29 CFR 1910.1030
Records of names, signatures, initials and codes used to identify which employee performed a test.	75 years	RCS 10-1;7100.29
Computer	三を見る。 200 日本日本日本日本日本日本日本日本日本日本日本日本日本日本日本日本日本日本日	
Computer preventative maintenance records: (daily/weekly/monthly)	2 years 2 years after retirement	CAP GEN. 43022, GEN. 20377
TRANS	of system  TRANSFUSION MEDICINE	
Mati	DISPOSITION	NOTES
Donor Records  Donor Testing:  ABO/Rh type, difficulty in typing  Allogeneic donor testing to detect unexpected antibodies to red	10 years	RCS 10-1; 7100.31 (5 years), TJC DC 02.04.01, CAP TRM.32250 & AABB 6.2A (10 years)
Control systems for donor testing	10 years	CAP TRM.32250, AABB 6.2A

Approved By: Kathy McLatchie

Doc Type: GDL-520

Warning! Uncontrolled on Paper

Version: 3.0

Document Status: Approved

Page 5 of 15

Donor identifying information, address, medical history and exam, informed consent, receipt of educational materials, infectious disease marker tests	75 years	RCS 10-1; 7100.28 (75 years) CAP TRM.32250 & AABB 6.2A (10 years)
Donor Deferral:	Indefinite	
Permanent deferral of donors	macinina	OSA 05 23 01 AYA & AARR 624 (industrial)
<ul> <li>Donors placed under surveillance or indefinite deferral (for</li> </ul>		Korragisary take a ready 0.24 (magnifile)
recipient protection)		
Severe adverse reaction to donation	10 years	AARR 67A
Notification to Donor of significant findings	10 years	CAP TRM 32750 AARR 6 2A
Identification of individuals performing each significant step in collection	10 years	
process, processing, compatibility testing and transportation of blood and components		
Blood and Blood Components		
Results of inspection of blood and components incoming, during storage and prior to release	10 years	RCS 10-1;7100.4, CAP TRM.32250 (5 years), & AABB 6.2A
Serologic confirmation of donor blood ABO/Rh	10 years	TJC QSA.05.22.01 (5 years), CAP TRM.32250 & AABB
Irradiation of cellular components	10 years	CAP TRM 32250 AARR 6 2R
Source/receipt to final disposition of unit, unique identification of each unit and ID of recipient if applicable	10 years	RCS 10-1; 7100.5 CAP TRM.32250, TJC QSA.05.22.01, AXA
Look back notification and records that track components subsequently identified as infectious, includes records related to quarantined blood and components	75 years	RCS 10-1; 7100.35 (75 years), CAP TRM.32250 & AABB 6.2A & (10 years)
Look back to identify recipients who may have been infected with HCV or HIV/disease reporting	10 years	CAP TRM.32250 & AABB & 6.2B (10 years)
Patient Records		
Specimens from blood donors (units) and recipients	7 days post- transfusion or 10 days after crossmatch	RCS 10-1; 7100.27, CAP Reference 1, AABB 5.11.4, TJC QSA.05.12.01 & AXA
Requests for blood and blood components & order for blood, component, tests and derivatives	5 years	AABB 6.2B, RCS 10-1; 7100.6

Approved By: Kathy McLatchie

Authored By: Valerie McDowell 10/18/2016

Doc Type: GDL-520

Warning! Uncontrolled on Paper

**Document Status: Approved** 

Page 6 of 15

Version: 3.0

RCS 10-1;/100.30, CAF GEN.20373 & COM.10300, 72 105	5 years	Superseded procedures (paper or electronic), manuals and publications
DOS 10 1-7100 20 CAR CEN 20275 & COM 10500 AARR	Talough and a state of the stat	Quality Records
AABB 6.2B (see standards for more details)	5 years	Verification at time of transfusion of all recipient and blood component information, special transfusion requirements & crossmatch interpretation,
AABB 6.2B (See standards for more details)	10 years	Verification process at time of issue of all recipient and blood component information, special transfusion requirements, crossmatch interpretation, date/time of issue and personnel issuing and accepting blood component.
AABB 6.2B	10 years 10 years	Apheresis or therapeutic phlebotomy records  Final Inspection of blood and blood components before issue (if container in not intact or components are abnormal in appearance, maintain medical director approval)
		<ul> <li>Transfusion record indicating ABO/Rh and compatibility testing, date/time of transfusion, transfusionist, vitals, component, unit#, amount given and adverse reactions if applicable</li> </ul>
RCS 10-1; 7100.28 (75 years), CAP TRM.32250 (10 years), AABB 6.2B & TJC DC.02.04.01(10 years)	75 years	Transfusion Record  • Verification of patient identification prior to transfusion  • Recipient Informed Consent
TJC DC 02.04.01&AXA	10 years	Test Reports including preliminary, final and corrected (See Note 2)
		<ul> <li>interpretation</li> <li>Testing and interpretation of serologic and computer crossmatch</li> <li>Immediate evaluation/interpretation of transfusion reaction</li> </ul>
RCS 10-1; 7100.31 (5 years); TJC DC 02.04.01, CAP TRM.32250 & AABB 6.2B (10 years)	10 years	Patient Testing  ABO/Rh type testing and interpretation  Testing to detect unexpected antibodies to red cell antigens and
	Indefinite	Difficulty in blood typing, significant antibodies, significant adverse events to transfusion (transfusion reactions), and special transfusion requirements
AABB 6.2B, CAP.32250	10 years	Emergency release of blood, including, signed statement from the requesting physician indicating that the clinical situation was sufficiently urgent to require release of blood before completion of compatibility testing

Approved By: Kathy McLatchie

Doc Type: GDL-520

Warning! Uncontrolled on Paper

Version: 3.0

Document Status: Approved

Page 7 of 15

labels, circulars, product inserts and computer manuals		6.2C, TJC AXA
Exceptions to policies, processes, and procedures	10 years	AABB 6.2C
Quality control records for:  • Reagents, blood and blood products, critical materials/supplies		AABB 6.2A, 6.2B & 6.2C (10 years), RCS 10-1; 7100.32 & 7100.33, CAP TRM.32250, & TJC AXA (5 years)
<ul> <li>Instruments,/equipment/methods</li> <li>Irradiation dose delivery</li> </ul>	10 years	AND JO, CAL LINE LIZZZOU, & LIC ANA (3 years)
Proficiency testing and corrective action as applicable	5 years	RCS 10-1; 7100.32, CAP TRM.32250, CAP COM.01700 & AABB 6.2C (5 years), TJC QSA.01.02.01 & AXA (2 years)
Container (i.e. portable coolers used to transport blood) qualifications and process validation records.	10 years	AABB 6.2C
Temperature monitoring of refrigerator, freezer and platelet incubators temperatures, ambient temperature (Blood and component storage temperatures)	10 years	AABB 6.2C ( 10 years), RCS 10-1; 7100.32 & 7100.33, CAP TRM.32250 &
Description and evaluation of nonconforming blood, blood components, tissue, derivatives, critical materials, and services including any corrective actions and acceptance for use. Disposition of nonconforming units	10 years	AABB 6.2C
Instrument validation, records of method performance specifications	10 years after	CAP GEN.20377 (Life+2yrs), AABB 6.2C (10 years after
	returement of the equipment	retirement of the equipment), RCS 10-1;7100.16 (2 years)
instrument preventative maintenance records: (daily/weekly/monthly/)	10 years	AABB 6.2C (10 years, considered QC records), CAP TRM.32250 (5 years). RCS 10-1-7100 20 & TIC EC 02 04 03
		(2 years)
scords (major repairs, parts and replacement) and	10 years after	RCS-10;7100.21 & TJC EC.02.04.03&AXA (life of
attituat iliatticetance	retirement of the equipment	instrument), AABB 6.2C (10 years after retirement of the equipment
Validation of new or changed process and procedures	5 years	AABB 6.2C
tion/validation	2 years after	CAP GEN.43022 & TRM.22000, AABB 6.2C
_	retirement of system	
Quality system and self-assessment audits (Quality management reviews)	5 years	CAP TRM.32250 & AABB 6.2C (5 years), RCS 10-1;7100.16

Approved By: Kathy McLatchie

Doc Type: GDL-520

Section: Guidelines

Authored By: Valerie McDowell 10/18/2016

Warning! Uncontrolled on Paper

Version: 3.0

**Document Status: Approved** 

Page 8 of 15

		& TJC DC.02.04.01 (2 years)
Fatality Reports	10 years	AABB 6.2C
Testing of emergency management plan at defined intervals	2 years	AABB 6.2C
Personnel		100 10 100 100 100 100 100 100 100 100
Staff qualifications, training and competency (as part of OPF)	30 years	RCS 10-1;7100.22 (30 years), AABB 6.2C (5 years)
Initial training on instrument/method	5 years	CAP GEN.20377 & GEN.55450, RCS-10;7100.22 & AABB 6.2C (5 years)
Annual Competency assessments	5 years	RCS 10-1;7100.22, AABB 6.2C & CAP TRM.32250 (CAP considers this a quality record)
Records of employee names, signatures, initials, and identification codes, and inclusive dates of employment for personnel who perform or	75 years	RCS 10-1;7100.29 (75 years), CAP TRM.32250 & AABB 6.2C (10 years)
review critical tasks		
Tissue Banking		
Ouality Control	5 years	IJC AXA
<ul> <li>Superseded procedures, manuals and publications</li> <li>Storage temperatures.</li> </ul>	10 years	TJC TS.03.02.01(10 years), TJC AXA; CAP TRM.32250 & TRM.45190 & COM.10500; RCS 10-1; 7100.36 & AABB 6.2C (5 years)
<ul> <li>Source facility/tissue supplier</li> <li>Original donor or lot identification (numeric or alphanumeric)</li> <li>All recipients</li> </ul>	75 years	RCS 10;7100.54 (75 years), CAP TRM.32250 & TRM.45190, TJC AXA, TS.03.02.01 (10 years post disposition or expiration date whichever is longer) & AABB 6.2D (10 years)
Date of transplantation or other final disposition		TIC A BB A A ABB A DEL TIC
Patient's medical record to include: type of tissue, the numeric or alphanumeric identifier, the quantity, expiration date, and date of use	10 years post disposition or expiration date whichever is longer	AABB 6.2D (Same for Derivatives see AABB 6.2D), 11C TS.03.02.01,
Collection, transportation, processing, issuing	10 years post disposition or expiration date whichever is longer	TRM.32250 & TJC TS.03.02.01 (10 years), AABB 6.2D (10 years - Same for Derivatives see AABB 6.2E)
Tissue Records including inspection of incoming tissue, requests, and adverse effects (see AABB standards for complete listing of required	10 years	AABB 6.2D (Same for Derivatives see AABB 6.2E), TJC TS.03.02.01, CAP TRM.45190
elements)		

Approved By: Kathy McLatchie

Doc Type: GDL-520

Warning! Uncontrolled on Paper

Version: 3.0

Document Status: Approved

Page 9 of 15

Traceability of tissue to final disposition	10 Years	AABB 6.2D (Same for Derivatives see AABB 6.2E), CAP TRM.45190, TJC TS.03.02.01
ANAT	ANATOMIC PATHOLOGY	
ITEM	NOTTISOPSIG	NOTES
Surgical Pathology	Service Contract	NOTES
Wet tissue	2 weeks after date of the final report	RCS 10-1;7100.39 & CAP ANP.12500 (2 weeks after date of the final report), TJC QSA.13.07.01 & AXA (7 days after report), 42CFR493 1105 (until diagnostic is made)
Paraffin blocks (See Note 8)	10 years from date of the exam	RCS 10-1;7100.38 & CAP ANP.12500 (10 years), TJC QSA.13.07.01 & AXA, 42CFR493.1105 (2 years from
Histopathology microscopic slides, including stained slides	25 years	RCS 10-1; 7100.37 (25 years), CAP ANP.12500, TJC QSA.13.07.01 & AXA, 42CFR493.1105 (10 years) slides
Surgical Pathology Control Slides	10 years	CAP ANP. 12500 slides must remain readable for this period
Immunohistochemistry batch control slide records	2 years	CAP ANP.22660
Flurochrome stained slides	At discretion of the Lab Director	CAP ANP.12500
Images of ISH studies - for neoplastic disorders (See Note 3)	10 years	CAP ANP 12500 & ANP 22965 TIC AXA
Images of ISH studies - for constitutional disorders (See Note 3)	20 years	CAP ANP.12500 & ANP.22965
Digital images used for primary diagnosis	10 years if original glass slides are not available	CAP ANP.12500
Datasets from In-Vivo Microscopy (IVM) or Ex Vivo Microscopy (EVM) systems used to aid in interpretation or diagnosis (See Note 12)	10 years - data must be retrievable for this period	CAP ANP.12500 & ANP.57850
Reports (Final, Modified) (See Note 4)	25 years	RCS 10-1;113-40 (25 years), CAP ANP.12500 & TJC DC.02.04.01&AXA (10 years) 42CFR493 1105 (10 years)
Reports of outside consultations on laboratory cases (whether or not	10 years after the date	CAP ANP.12500

Approved By: Kathy McLatchie

Authored By: Valerie McDowell 10/18/2016

Doc Type: GDL-520

Warning! Uncontrolled on Paper

Document Status: Approved

Page 10 of 15

Version: 3.0

I chiresian of the important)	was issued	
Accession log records	5 years	RCS 10-1;7100.41 (5 years), CAP ANP.12500 (2 years)
Cytopathology		
	10 years (suspicious cell blocks 25 years)	VHA Handbook 1106.01 (10 years) CAP CYP.06900 (Same as slides)
Slides (negative, unsatisfactory)	5 years	RCS 10-1; 7100.43, CAP CYP.06900, TJC AXA & QSA.08.09.01, 42CFR493.1105
Slides (suspicious, positive)	25 years	RCS 10-1;7100.44 (25 years), CAP CYP.06900 & TJC AXA & QSA 08.09.01, 42CFR493.1105 (5 years)
Fine Needle Aspiration Slides	25 years	RCS 10-1;7100.45 (25 years), CAP CYP.06900 & TJC AXA (10 years)
Reports (Final, Modified) (See Note 4)	25 years	RCS 10-1;7100.46 (25 years), CAP CYP.06600 (at least 10 years), TJC DC 02.04.01& AXA (10 years)
Accession log reports	5 years	RCS 10-1;7100.47 (5 years), CAP & CYP.06600 (5 years newly identified abnormality in cervical cytopathology)
Records of intra and extra-departmental consultations	10 years	CYP.02100
slides or images for neoplastic disorders (See Note	10 years	CAP MOL.39288
nages of ISH assays slides or images for constitutional disorders (See ote 3)	20 years	CAP MOL.39288
ports for neoplastic conditions - (A copy of each final report, ords of results, membranes, autoradiographs, gel graphs, and in situ hybridization slides)	10 years	CAP MOL.49640
Test Reports for constitutional disorders - (A copy of each final report, all records of results, membranes, autoradiographs, gel photographs and in vitu hybridization slides)	20 years	CAP MOL.49640
ary to support primary	2 years	CAP MOL.35870

Approved By: Kathy McLatchie

Doc Type: GDL-520

Warning! Uncontrolled on Paper

Version: 3.0

Document Status: Approved

Page 11 of 15

Wet tissue    Paraffin blocks (See Note 9)		
In blocks (See Note 9)  Is (Provisional, Final, Modified)  ITEM  ITEM  In specimens and cultures  ISSE Specimens or cell pellets  In the stained slides  In the	6 months after date	RCS
in blocks (See Note 9)  IS (Provisional, Final, Modified)  ITEM  IS (Provisional, Final, Modified)  IS (Pr	final report	ANP.33500 (3 months from final report)
sion log records  ITEM  ITEM  al specimens and cultures  ssed specimens or cell pellets  mently stained slides  hrome stained slides & Cytogenomic array slides enomic array data- original scan  enomic array data- sufficient original data to support the final ives, prints or digitized images ses or permanent slides of ISH studies - (hard copy negatives ont) and/or in retrievable digitized formats- non-		RCS 10-1; 7100.49 (10 years after date of final report), CAP
ITEM  Sion log records  ITEM  ITEM  ITEM  ITEM  Inal specimens and cultures  ssed specimens or cell pellets  mently stained slides  chrome stained slides & Cytogenomic array slides  chromic array data- original scan  cenomic array data- sufficient original data to support the final ives, prints or digitized images  negatives, prints or magnetic media of abnormal cases  es or permanent slides of ISH studies - (hard copy negatives ont) and/or in retrievable digitized formats- non-		
sion log records  ITEM  al specimens and cultures  ssed specimens or cell pellets  mently stained slides & Cytogenomic array slides  chrome stained slides & Cytogenomic array slides  enomic array data- original scan  enomic array data- sufficient original data to support the final ives, prints or digitized images  negatives, prints or magnetic media of abnormal cases es or permanent slides of ISH studies - (hard copy negatives ont) and/or in retrievable digitized formats- non-	25 years after date	RCS 10-1; 7100.50 (25 years after date of final report), CAP
omic array slides  ginal data to support the final edia of abnormal cases studies - (hard copy negatives ized formats- non-	final report	
omic array slides  ginal data to support the final ginal cases studies - (hard copy negatives ized formats - non-		RCS 10-1;7100.51 (25 years after date of final report), CAP
ort the final cases copy negatives on-		
ort the final cases copy negatives on-		Materials" & TJC DC 02.04.01&AXA (10 years)
ort the final cases copy negatives on-	5 years after date of	RCS 10-1;7100.52 (5 years after date of final report), CAP
ort the final cases copy negatives on-	final report	ANP.33500 (2 years)
ort the final cases copy negatives on-	CYTOGENETICS	
ort the final cases copy negatives on-		NOTES
ort the final cases copy negatives on-		CAP CYG.32700 (until release of final report), TJC
ort the final cases copy negatives on-		QSA.09.06.01(Until adequate metaphase cells are available)
ort the final cases copy negatives on-		CAP CYG.32700 & TJC QSA.09.06.01(2 weeks after release
ort the final cases copy negatives on-		of final report)
ort the final cases copy negatives on-		CAP CYG.32700, TJC QSA.09.06.01
ort the final cases copy negatives on-		CAP CYG.32700
e final		
e final		CAP CYG.32700
e final	compiete	
negatives		CAP CYG.32700
negatives		, TJC QSA.09.06.01
negatives		TJC QSA.09.06.01
or prints) and/or in retrievable digitized formats- non-	negatives	CAP CYG.32700
	trievable digitized formats- non-	
neoplastic/constitutional disorders (See Note 5)	nal disorders (See Note 5)	

Approved By: Kathy McLatchie

Doc Type: GDL-520

Authored By: Valerie McDowell 10/18/2016

Warning! Uncontrolled on Paper

Version: 3.0

Document Status: Approved

Page 12 of 15

Images or permanent slides of ISH studies - (hard copy negatives or prints) and/or in retrievable digitized formats- neoplastic disorders (See Note 5)	10 years	CAP CYG.32700
Final Report	20 years	CAP CYG.32700 (10 years neoplastic conditions, 20 years constitutional/genetic conditions), TJC QSA.09.06.01(20 years) & AXA (25 years suggested)
ELECT	ELECTRON MICROSCOPY	
ITEM	DISPOSITION	NOTES
Written Accession log records	5 years	CAP ANP.55100 (2 years), VHA Handbook 1106.01 (5 years)
Electronic Accession log (Vista)	25 years after	VHA Handbook 1106.01
Wet tissue	2 weeks after final	CAP ANP.55100, VHA Handbook 1106.01
	report	
Resin/plastic blocks	25 years from date of	CAP ANP.55100 (10 years), VHA Handbook 1106.01 (25
	exam	years from date of exam)
EM grids	10 years	CAP ANP.55100 (10 years), VHA Handbook 1106.01 (1 year)
Negatives, or electronic images (all images, local EM Unit archive with	25 years after final	CAP ANP.55100 (10 years), VHA Handbook 1106.01 (25
optical or other media back-up), which are part of the report and written reports	report	years after final report)
Digital Images which are part of the reports and electronic reports (VistA, CPRS)	Retained within patient electronic record 75	VHA Handbook 1106.01
	years after last episode of care	
Prints from negatives included with report	10 years along with the report	VHA Handbook 1106.01
Remaining prints from negatives	l year after final report	VHA Handbook 1106.01
Maintenance records	2 calendar years	VHA Handbook 1106.01
Semi-thin section (glass slides)	25 year from date of	VHA Handbook 1106.01
	exam	

Approved By: Kathy McLatchie

Doc Type: GDL-520

Authored By: Valerie McDowell 10/18/2016

Warning! Uncontrolled on Paper

Version: 3.0

**Document Status: Approved** 

Page 13 of 15

generated at the time of testing in order to be considered satisfactory for compliance. (TJC:DC.02.04.01) (CAP:GEN.20377). Note: Retained records may be paper or electronic. Electronic systems must be able to retrieve all information printed on the original hard copy paper print-out available, or 2) manually performed test methods without worksheets, the two-year retention requirement applies to the data within the computer retention of all worksheets, printouts, etc. for at least two years. For results that are manually entered into the computer from 1) observation of an electronic display, with no printouts, etc., so long as the computer retains the data for at least two years. Manual computer entry of patient result data from worksheets, print-outs, etc. requires NOTE 1: For data directly transmitted from instruments to the laboratory computer system via an interface (on-line system), it is not necessary to retain paper worksheets,

maintained in a computer system, microfilm, or microfiche record. A manual log containing duplicate information is also acceptable. For tests requiring an authorized signature or containing individual identifiers, the copy includes the signature or individual identifiers. (TJC:DC 02.04.01) NOTE 2: Original test report or an exact copy. The exact copy includes the name and address of the laboratory performing the test. The copy may be on paper or

cells illustrating each relevant abnormal probe signal pattern (CAP ANP.12500 & ANP.22965) with a normal result, retain an image of at least one cell illustrating the normal probe signal pattern. For an ISH assay with an abnormal result, retain images of at least two NOTE 3: There is no retention requirement for images of slide preparations when the source slides remain readable for the required retention period. For an ISH assay

electronic signature. Images of paper reports, such as microfiche or PDF files are acceptable (CAP ANP. 12500) NOTE 4: Pathology reports may be retained in either paper or electronic format. If retained in electronic format alone, the reports must include a secure pathologist

source slides remain readable for the required retention period. (CAP CYG.32700) retain images of at least two cells illustrating each relevant abnormal probe signal pattern. There is no retention requirement for images of slide preparations when the NOTE 5: For an ISH assay with a normal result, retain an image of at least one cell illustrating the normal probe signal pattern. For an ISH assay with an abnormal result,

NOTE 6: Records Retention for Proficiency Testing, TJC Q&A, March 21, 2011 How long should we keep proficiency testing records?

probably little value in retaining it longer than the required two years. unsuccessful status within that timeframe. If all proficiency testing performance was satisfactory beyond the minimum two year regulatory retention period, then there is that laboratories retain non-waived proficiency testing records by specialty and subspecialty for a five year period, particularly if there has been unsatisfactory or Plan of Action for a current unsuccessful event that also addresses any unsuccessful events that occurred in the prior five year period. For this reason, it is recommended proficiency testing performance is monitored for subsequent unsuccessful status for up to a five year period. In rare instances, a laboratory could be required to provide a A. For non-waived testing, the minimum retention requirement is two years for both Joint Commission standards and regulatory compliance. However, non-waived

waived proficiency testing records beyond two years is at the determination of the laboratory director. Note that this recommendation is specifically intended for non-waived testing. Participation in proficiency testing for waived testing is voluntary. Thus the value of retaining

Approved By: Kathy McLatchie

Authored By: Valerie McDowell 10/18/2016

Doc Type: GDL-520

Warning! Uncontrolled on Paper

Version: 3.0

Page 14 of 15

**Document Status: Approved** 

as some record of the identity (chemical name if known) of the substance or agent, where it was used, and when it was used is retained for at least thirty (30) years; NOTE 7: Material safety data sheets and paragraph (c) (5) (iv) records concerning the identity of a substance or agent need not be retained for any specified period as long

1910.1200(g). (29 CFR 1910.1020) Material safety data sheets must be kept for those chemicals currently in use that are effected by the Hazard Communication Standard in accordance with 29 CFR

that, whenever feasible, tissue block retention from patients with diagnosed malignancies be retained beyond the 10 year requirement. (CAP ANP.12500) survival rates are increasing and the continued emergence of treatment based on biomarker testing, which at times may be required on the original tissue, it is recommended NOTE 8: Paraffin blocks used for patient diagnostic purposes must be kept for at least 10 years and be stored in a manner that preserves their integrity. Given that patient

permanent storage may be considered. (CAP ANP.33500) members and public health. Strategies, such as retaining even a select number of blocks from each case permanently or partnering with a regional biorepository for however, it is not a requirement of accreditation. These blocks represent the last opportunity for tissue-based biomarker, genetic, and other testing in the interest of family NOTE 9: For autopsy paraffin blocks, the CAP recommends extending the required retention period to indefinitely or for at least a generation (approximately 20 years);

immunodeficiency evaluations for 10 years. Paper copies of gated dot plots and histograms are not required as long as the information is available electronically (e.g., .pdf, NOTE 10: The intent of this checklist requirement is retention of gated dot plots and histograms of hematolymphoid neoplasias, CD34 stem cell records, and congenital .tiff, .jpeg files). (CAP FLO.23706)

considered quality control records. However, the laboratory does need to define a minimum retention time for the packing lists that is reasonable and based on good lab our phone conversation this morning, this issue was discussed at our February 10, 2014 staff meeting. As a result of our discussion, it was agreed that packing lists are NOT NOTE 11: E-mail Response from Marian Briggs at CAP: "Thank you for your patience in awaiting my response regarding the retention of packing lists. As stated during

specimens that have been removed from the patient (EVM). The dataset refers to digitized or analog video or still images or other data (e.g. spectroscopic data) generated by spectroscopy/spectroscopic imaging, and similar technologies. These systems may be used by physicians during procedures (IVM) or by the laboratory in the evaluation of used to aid in interpretation or diagnosis. (CAP ANP.12500) IVM datasets are stored as digital files. Storage of the entire original data is not required. Stored data should an IVM or EVM system. If such data is used to aid in interpretation or diagnosis, record retention requirements apply. Stored data should include, at a minimum, the data NOTE 12: In Vivo Microscopy (IVM) and Ex Vivo Microscopy (EVM) systems include confocal microscopy, optical coherence tomography, multiphoton microscopy, optical include, at a minimum, the critical data elements(original data or derived data) used for interpretation or diagnosis (CAP ANP.57850)

Approved By: Kathy McLatchie

Doc Type: GDL-520

Authored By: Valerie McDowell 10/18/2016

Warning! Uncontrolled on Paper

Version: 3.0

Page 15 of 15

**Document Status: Approved** 

#### References:

- "Retention of Laboratory Records and Materials", CAP Website, Revised June 2013
- CAP Checklists, 8/17/2016
- "Standards for Blood Banks and Transfusion Services" AABB 30th edition
- Record Control Schedule (RCS-10), May 2016
- 6.5 "Comprehensive Accreditation Manual for Laboratory and Point of Care Testing", The Joint Commission, 7/1/2016
- "Appendix A: Retention Times for Records, Reports, and Specimens (AXA)", The Joint Commission, 7/1/2016
- Electronic Code of Federal Regulations, Title 42-Public Health, e-CFR Data current as of 10/17/2016
- Electronic Code of Federal Regulations, Title 29-Labor, e-CFR Data current as of 10/17/2016 Electronic Code of Federal Regulations, Title 21-Food and Drugs, e-CFR Data current as of 10/17/2016
- VHA Handbook 1106.01, 1/29/2016

#### Document Revisions

V3.0		10/18/2016
	Tissue Banking: Collection, transportation, processing, issuing 10 years post disposition	
V 3.0	Initial training on an instrument/method 5 years	10/18/2016
V 3.0	validation of electronic/procedure/built-in QC) 2 years after discontinuation of the test	10/18/2016
V 3.0	of IQCP, may be implemented by the laboratory to allow for the use of streamlined QC for commercial microbial identification systems (MIS)	10/18/2016
New Version Number	Description of Revision	Revision

Approved By: Kathy McLatchie

Authored By: Valerie McDowell 10/18/2016

Doc Type: GDL-520